Antonio Decarli, MD
Gastroenterology · New Smyrna Beach, FLNPI 1376644328
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,890 of the $6,426 with a category attached, or 76.1%. 31 manufacturers reported payments, led by AbbVie at 54.2% of the total. 2025 is the largest year on record at $2,479, 9.6 times the $258 reported in 2019.
Across 269 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$413
- Takeda Pharmaceuticals U.S.A., Inc.$339
- Celltrion USA Inc.$279
- Ipsen Biopharmaceuticals, Inc$259
- Braintree Laboratories, Inc.$220
- plus $1K from 25 others
Across 17 payments — averaging $11,128 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$140K
- Bristol Myers Squibb$49K
What the payments were for
- Speaking & faculty fees$1,49923%
- Food & beverage$4,89076%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 123 | $3,483 |
| Johnson & Johnson | 24 | $413 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $339 |
| Celltrion USA Inc. | 15 | $279 |
| Ipsen Biopharmaceuticals, Inc | 5 | $259 |
| Braintree Laboratories, Inc. | 10 | $220 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $217 |
| Ferring Pharmaceuticals Inc. | 11 | $174 |
| Merck | 6 | $116 |
| Evoke Pharma, Inc. | 6 | $113 |
| Intercept Pharmaceuticals, Inc. | 5 | $96 |
| Aimmune Therapeutics, Inc. | 2 | $61 |
| Gilead | 3 | $61 |
| Phathom Pharmaceuticals, Inc. | 1 | $59 |
| Sanofi | 3 | $57 |
| Nestle Healthcare Nutrition Inc. | 3 | $50 |
| Ironwood Pharmaceuticals, Inc | 3 | $48 |
| Vivus LLC | 3 | $48 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Novo Nordisk | 2 | $45 |
| Medtronic | 2 | $41 |
| Axonics, Inc. | 2 | $31 |
| Ardelyx, Inc. | 1 | $25 |
| Enterra Medical, Inc. | 1 | $24 |
| Pfizer | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Teleflex LLC | 1 | $20 |
| QOL Medical, LLC | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Romark Laboratories, LC | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,426 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 26 | $137,293 |
| LinzessLinaclotide | 46 | $41,586 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 80 | $9,787 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 36 | $6,041 |
| Mesalamine | 23 | $4,807 |
| Pantoprazole Sodium | 225 | $3,039 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 115 | $2,087 |
| Famotidine | 105 | $1,665 |
| Omeprazole | 74 | $1,176 |
| Dicyclomine Hcl | 32 | $899 |
| Esomeprazole Magnesium | 22 | $616 |
| Sulfasalazine | 14 | $562 |
| Ondansetron Hcl | 19 | $468 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 15 | $437 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 26 | $431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $3,483 | $178,87972 claims |
| Braintree Laboratories, Inc.Suflave | $220 | $9,78780 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $174 | $6,04136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in New Smyrna Beach
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
- Arin NewmanMiami Beach$716K
- Joanna LopezMiami$670K
- Jose NietoSebring$573K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.